BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-5@catalystbrief.girapphe.com
DTSTAMP:20261117T061844Z
LAST-MODIFIED:20261117T061844Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: Merck Sharp & Dohme LLC (MRK) — Pembrolizumab [Nov 2026]
DESCRIPTION:Phase 3 primary completion: Pembrolizumab (MK-3475) with chemor
 adiotherapy in MIBC (KEYNOTE-992).\nSource: https://clinicaltrials.gov/stu
 dy/NCT04634877\nhttps://catalystbrief.girapphe.com/e/5?lang=en\nNot invest
 ment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/5?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
